Showing results (131-140 of 154) with videos related to
Sort By:
Pageof 16
Brain Communications|June 19, 2026
Acute and longitudinal magnetic resonance imaging abnormalities in antibody-mediated encephalitisNabil Seery, Paul Beech, Robb Wesselingh, et al.Journal of Neurology|April 25, 2025
Multimodal prognostication of autoimmune encephalitis: an Australian autoimmune encephalitis consortium studyNabil Seery, Robb Wesselingh, Paul Beech, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|April 7, 2017
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysisAlessio Signori, Guillermo Izquierdo, Alessandra Lugaresi, et al.Cardiovascular Diabetology|March 20, 2024
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomesOliver Schnell, Katharine Barnard-Kelly, Tadej Battelino, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.Brain : a Journal of Neurology|January 25, 2015
Genetic variants are major determinants of CSF antibody levels in multiple sclerosisAn Goris, Ine Pauwels, Marte W Gustavsen, et al.Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.Journal of Neurology|September 28, 2023
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategiesYing Li, Alice Saul, Bruce Taylor, et al.JAMA Neurology|July 12, 2023
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple SclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.Pageof 16